Abstract Number: LB13 • ACR Convergence 2025
Obinutuzumab Leads to Deep B-Cell Depletion in the Kidney Parenchyma of Patients With Lupus Nephritis: An Exploratory Analysis of the REGENCY Trial
Background/Purpose: B cells infiltrate the kidneys in lupus nephritis (LN) and likely contribute to the pathogenesis of kidney injury. The REGENCY trial (NCT04221477) showed that…Abstract Number: 0139 • ACR Convergence 2025
When One Isn’t Enough: Does Adding IgM Worsen the Antiphospholipid Syndrome Phenotype?
Background/Purpose: Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by the persistent presence of antiphospholipid antibodies (aPL) along with clinical manifestations such as venous…Abstract Number: 0131 • ACR Convergence 2025
Libman-Sacks Endocarditis in APS: A Case-Control Study of Clinical and Serologic Features
Background/Purpose: Libman-Sacks endocarditis (LSE) is an inflammatory phenomenon, typically involving the mitral or aortic valve, that affects some patients with systemic lupus erythematosus (SLE) and/or…Abstract Number: 0132 • ACR Convergence 2025
Increased Expression of Gas6 and Its Tyrosine Kinase Receptor Tyro3 Are Associated with Antiphospholipid Syndrome
Background/Purpose: Growth arrest specific protein 6 (Gas6) is a member of the vitamin K-dependent protein family. It participates in apoptosis, inflammatory response and immunomodulation by…Abstract Number: 0140 • ACR Convergence 2025
Outcome Of Patients With Non-Criteria Manifestations Of Primary Antiphospholipid Syndrome Treated With Immunosuppressants -A Single Centre Study
Background/Purpose: Non-criteria manifestations occur in 24% in Primary antiphospholipid syndrome (PAPS) . The efficacy of immunosuppressants in patients with above condition is not certain due…Abstract Number: 0136 • ACR Convergence 2025
Beyond Thrombosis: Histological Spectrum, Predictors and Outcomes of Renal Involvement in Primary Antiphospholipid Syndrome: A Single-Centre Cohort Study
Background/Purpose: Renal involvement in primary APS is underrecognized and histologically diverse, encompassing both vascular and glomerular pathology. We aimed to describe the histopathology, outcomes of…Abstract Number: 0130 • ACR Convergence 2025
Plasminogen activator inhibitor 1 increases thrombotic risk in Antiphospholipid syndrome
Background/Purpose: Antiphospholipid antibody syndrome (APS) is a common cause for acquired thrombophilia. The group termed ‘seronegative’ APS has not made any headway in the revised…Abstract Number: 0138 • ACR Convergence 2025
Evaluating Artificial Intelligence for Diagnosing Antiphospholipid Syndrome in Pulmonary Embolism Case Reports: A Prompt-Based Analysis
Background/Purpose: Antiphospholipid syndrome (APS) is a complex autoimmune prothrombotic disorder that can present with venous or arterial thromboses, often masquerading as unprovoked pulmonary embolism (PE).…Abstract Number: 0135 • ACR Convergence 2025
Rituximab in Antiphospholipid Syndrome: aPL Titer Decline and Clinical Outcomes
Background/Purpose: Rituximab treatment has been shown to be effective in non-thrombotic manifestations of APS and refractory catastrophic APS (CAPS). However, there are conflicting results regarding…Abstract Number: 0134 • ACR Convergence 2025
Neutrophil Gasdermin D Pores as Potential Therapeutic Targets in APS-Associated Thromboinflammation
Background/Purpose: Emerging evidence implicates neutrophil activation and neutrophil extracellular trap (NET) formation (i.e., NETosis) in amplifying APS-associated thromboinflammation. Gasdermin D (GSDMD), a substrate of inflammatory…Abstract Number: 0133 • ACR Convergence 2025
Differences in cardiovascular risk factor control between primary and systemic lupus erythematosus-related antiphospholipid syndrome in a multiethnic cohort of 1003 patients with antiphospholipid syndrome: the SUrvey of cardiovascular disease Risk Factors (SURF) in SLE and APS project
Background/Purpose: Cardiovascular disease (CVD) in antiphospholipid syndrome (APS) is driven by antiphospholipid antibody-mediated immunothrombotic mechanisms and traditional cardiovascular risk factors (CVRFs). Although the EULAR recommendations…Abstract Number: 0129 • ACR Convergence 2025
Analysis of Antiphosphatidylserine/prothrombin Antibodies as a Predictor of Lupus Anticoagulant in the Pediatric Population
Background/Purpose: Antiphospholipid Syndrome (APS) is a systemic thromboinflammatory autoimmune disease characterized by thrombotic or obstetric events occurring in individuals with persistently positive antiphospholipid antibodies (aPL).…Abstract Number: 0128 • ACR Convergence 2025
Defining a Consensus for Critical Data Fields for International Pediatric Antiphospholipid Syndrome Research
Background/Purpose: Pediatric antiphospholipid syndrome (APS) is a rare, thrombo-inflammatory autoimmune disease characterized by thrombosis and nonthrombotic manifestations in patients with persistent positive antiphospholipid antibodies, with…Abstract Number: 0137 • ACR Convergence 2025
Landscape of Primary Antiphospholipid Syndrome: Clinical Spectrum, Serology, and Predictors of Damage in a Single Center Cohort of 233 Patients
Background/Purpose: Primary Antiphospholipid Syndrome (APS) a systemic autoimmune prothrombotic disorder with long-term consequences. While secondary APS is well studied, large real-world cohorts of primary APS…Abstract Number: 0127 • ACR Convergence 2025
Single-cell Profiling of Dermal Endothelial Cells Reveals Potential Cell-Cell Interactions in Patients with APS and a History of Cardiac Valve Disease
Background/Purpose: Some of the rarer manifestations of antiphospholipid syndrome (APS), such as cardiac valve disease, remain poorly understood at the molecular level. A previous study…
- « Previous Page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- …
- 2616
- Next Page »